SCHEMBL4239176

SCHEMBL4239176

COc1ccc(CN2CCc3nc(NC(=O)c4cccc5[nH]c(N)nc45)sc3C2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.51
ALDH1A1 P00352 7/20 0.51
KDM4E B2RXH2 6/20 0.51
RAB9A P51151 5/20 0.51
SMN1; SMN2 Q16637 4/20 0.51
KMT2A Q03164 4/20 0.51
MEN1 O00255 3/20 0.51
GAA P10253 6/20 0.49
NPC1 O15118 3/20 0.49
MAPK1 P28482 1/20 0.49
CYP2C19 P33261 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2D6 P10635 1/20 0.46
HPGD P15428 1/20 0.46
USP2 O75604 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
PPARG P37231 1/20 0.43
NCOA2 Q15596 1/20 0.43
NCOA1 Q15788 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4246137 0.92 RAB9A (0.51) MAPTALDH1A1KDM4ERAB9ASMN1; SMN2
SCHEMBL4239433 0.92 MAPT (0.49) MAPTALDH1A1KDM4ERAB9ASMN1; SMN2
SCHEMBL4239162 0.91 MAPT (0.50) MAPTALDH1A1KDM4ERAB9ASMN1; SMN2
SCHEMBL4239713 0.91 MAPT (0.54) MAPTALDH1A1KDM4ERAB9ASMN1; SMN2
SCHEMBL4244264 0.90 MAPT (0.58) MAPTALDH1A1KDM4ERAB9ASMN1; SMN2
SCHEMBL4240699 0.89 RAB9A (0.47) MAPTALDH1A1KDM4ERAB9ASMN1; SMN2
SCHEMBL4243661 0.87 MAPT (0.47) MAPTALDH1A1KDM4ERAB9ASMN1; SMN2
SCHEMBL4244559 0.86 ALDH1A1 (0.51) MAPTALDH1A1KDM4ERAB9ASMN1; SMN2
SCHEMBL4243788 0.86 MAPT (0.51) MAPTALDH1A1KDM4ERAB9ASMN1; SMN2
SCHEMBL6104300 0.85 ALDH1A1 (0.52) MAPTALDH1A1KDM4ERAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8946259-B2 Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors HIGH POINT PHARMACEUTICALS, LLC (US) 2015-02-03 US disclosed
US-20140066477-A1 Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors HIGH POINT PHARMACEUTICALS, LLC (US) 2014-03-06 US disclosed
US-8598353-B2 Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors HIGH POINT PHARMACEUTICALS, LLC (US) 2013-12-03 US disclosed
EP-2457901-A1 Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors High Point Pharmaceuticals, LLC (US) 2012-05-30 EP disclosed
US-20090326006-A1 Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors VTVX HOLDINGS II LLC 2009-12-31 US disclosed
US-20060223849-A1 Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors HIGH POINT PHARMACEUTICALS, LLC 2006-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326006-A1 Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors BACE1, BACE2, APP MAPT 85/4885ALDH1A1 1717/4885KDM4E 3510/4885
US-20060223849-A1 Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors BACE1, BACE2, APP MAPT 85/4885ALDH1A1 1717/4885KDM4E 3510/4885
US-20140066477-A1 Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors BACE1, BACE2, APP MAPT 85/4885ALDH1A1 1717/4885KDM4E 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.